Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT01167426
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT01049984
- Locations
- 🇺🇸
Teva Investigational Site 21, Medford, Oregon, United States
🇺🇸Teva Investigational Site 31, Charlotte, North Carolina, United States
🇺🇸Teva Investigational Site 09, Richmond, Virginia, United States
Therapy Optimization in Multiple Sclerosis (MS)
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 2878
- Registration Number
- NCT00819000
- Locations
- 🇺🇸
Teva Investigational Site, Carnegie, Pennsylvania, United States
A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00455260
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00399477
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 307
- Registration Number
- NCT00240006
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00239993
- Locations
- 🇺🇸
Neurological Center of South Florida, Miami, Florida, United States
🇺🇸Advanced Neurosciences Institute, Nashville, Tennessee, United States
🇺🇸Multiple Sclerosis Care Center, Brooklyn, New York, United States
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
Completed
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT00238654
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00220922
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT00203060
© Copyright 2024. All Rights Reserved by MedPath